These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34605370)

  • 1. Initial Adaptation of the General Cognitive Assessment Battery by Cognifit™ for Bulgarian Older Adults.
    Yaneva A; Massaldjieva R; Mateva N
    Exp Aging Res; 2022; 48(4):336-350. PubMed ID: 34605370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of digital clock drawing test in comparison with CERAD neuropsychological battery total score for discrimination of patients in the early course of Alzheimer's disease from healthy individuals.
    Müller S; Herde L; Preische O; Zeller A; Heymann P; Robens S; Elbing U; Laske C
    Sci Rep; 2019 Mar; 9(1):3543. PubMed ID: 30837580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A total score for the CERAD neuropsychological battery.
    Chandler MJ; Lacritz LH; Hynan LS; Barnard HD; Allen G; Deschner M; Weiner MF; Cullum CM
    Neurology; 2005 Jul; 65(1):102-6. PubMed ID: 16009893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: a prospective AddNeuroMed study.
    Paajanen T; Hänninen T; Tunnard C; Hallikainen M; Mecocci P; Sobow T; Tsolaki M; Vellas B; Lovestone S; Soininen H
    J Alzheimers Dis; 2014; 39(3):679-90. PubMed ID: 24246420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 Years and Counting.
    Fillenbaum GG; Mohs R
    J Alzheimers Dis; 2023; 93(1):1-27. PubMed ID: 36938738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The assessment of changes in cognitive functioning: age-, education-, and gender-specific reliable change indices for older adults tested on the CERAD-NP battery: results of the German Study on Ageing, Cognition, and Dementia in Primary Care Patients (AgeCoDe).
    Stein J; Luppa M; Luck T; Maier W; Wagner M; Daerr M; van den Bussche H; Zimmermann T; Köhler M; Bickel H; Mösch E; Weyerer S; Kaufeler T; Pentzek M; Wiese B; Wollny A; König HH; Riedel-Heller SG
    Am J Geriatr Psychiatry; 2012 Jan; 20(1):84-97. PubMed ID: 22183013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of age, education and gender in the Consortium to Establish a Registry for the Alzheimer's Disease (CERAD)-Neuropsychological Assessment Battery for Cantonese-speaking Chinese elders.
    Liu KP; Kuo MC; Tang KC; Chau AW; Ho IH; Kwok MP; Chan WC; Choi RH; Lam NC; Chu MM; Chu LW
    Int Psychogeriatr; 2011 Dec; 23(10):1575-81. PubMed ID: 21729408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging.
    Roalf DR; Moberg PJ; Xie SX; Wolk DA; Moelter ST; Arnold SE
    Alzheimers Dement; 2013 Sep; 9(5):529-37. PubMed ID: 23260866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Validity and reliability of the CERAD-Col neuropsychological battery].
    Aguirre-Acevedo DC; Gómez RD; Moreno S; Henao-Arboleda E; Motta M; Muñoz C; Arana A; Pineda DA; Lopera F
    Rev Neurol; 2007 Dec 1-15; 45(11):655-60. PubMed ID: 18050096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB).
    Mistridis P; Egli SC; Iverson GL; Berres M; Willmes K; Welsh-Bohmer KA; Monsch AU
    Eur Arch Psychiatry Clin Neurosci; 2015 Aug; 265(5):407-17. PubMed ID: 25555899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.
    Ayutyanont N; Langbaum JB; Hendrix SB; Chen K; Fleisher AS; Friesenhahn M; Ward M; Aguirre C; Acosta-Baena N; Madrigal L; Muñoz C; Tirado V; Moreno S; Tariot PN; Lopera F; Reiman EM
    J Clin Psychiatry; 2014 Jun; 75(6):652-60. PubMed ID: 24816373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability and concurrent validity of Alzheimer's disease assessment scale - Cognitive subscale, Chinese version (ADAS-Cog-C) among Chinese community-dwelling older people population.
    Jiang Y; Yang H; Zhao J; Wu Y; Zhou X; Cheng Z
    Clin Neuropsychol; 2020 Dec; 34(sup1):43-53. PubMed ID: 32279575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CERAD-neuropsychological battery in screening mild Alzheimer's disease.
    Sotaniemi M; Pulliainen V; Hokkanen L; Pirttilä T; Hallikainen I; Soininen H; Hänninen T
    Acta Neurol Scand; 2012 Jan; 125(1):16-23. PubMed ID: 21198445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability and Validity of a Tablet-Based Neuropsychological Test (the Hellocog) for Screening Dementia.
    Seok DH; Yang HW; Han JW; Lim JH; Kim SH; Kim EY; Kim KW
    Psychiatry Investig; 2024 Jun; 21(6):655-663. PubMed ID: 38960443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CERAD Neuropsychological Battery in Patients with Idiopathic Normal Pressure Hydrocephalus Compared with Normal Population and Patients with Mild Alzheimer's Disease.
    Nerg O; Junkkari A; Hallikainen I; Rauramaa T; Luikku A; Hiltunen M; Jääskeläinen JE; Leinonen V; Hänninen T; Koivisto A
    J Alzheimers Dis; 2021; 81(3):1117-1130. PubMed ID: 33896842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norms and the effects of demographic variables on a neuropsychological battery for use in healthy ageing Australian populations.
    Collie A; Shafiq-Antonacci R; Maruff P; Tyler P; Currie J
    Aust N Z J Psychiatry; 1999 Aug; 33(4):568-75. PubMed ID: 10483853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of verbal episodic memory measures: consortium to establish a registry for Alzheimer's disease--Neuropsychological Assessment Battery (CERAD-NAB) versus California Verbal Learning Test (CVLT).
    Beck IR; Gagneux-Zurbriggen A; Berres M; Taylor KI; Monsch AU
    Arch Clin Neuropsychol; 2012 Aug; 27(5):510-9. PubMed ID: 22718104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can the CERAD neuropsychological battery be used to assess cognitive impairment in Parkinson's disease?
    Camargo CHF; Bronzini A; Tolentino ES; Medyk C; Schultz-Pereira GL
    Arq Neuropsiquiatr; 2018 Mar; 76(3):145-149. PubMed ID: 29809231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional abilities and cognitive decline in adult and aging intellectual disabilities. Psychometric validation of an Italian version of the Alzheimer's Functional Assessment Tool (AFAST): analysis of its clinical significance with linear statistics and artificial neural networks.
    De Vreese LP; Gomiero T; Uberti M; De Bastiani E; Weger E; Mantesso U; Marangoni A
    J Intellect Disabil Res; 2015 Apr; 59(4):370-84. PubMed ID: 24397351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total scores of the CERAD neuropsychological assessment battery: validation for mild cognitive impairment and dementia patients with diverse etiologies.
    Seo EH; Lee DY; Lee JH; Choo IH; Kim JW; Kim SG; Park SY; Shin JH; Do YJ; Yoon JC; Jhoo JH; Kim KW; Woo JI
    Am J Geriatr Psychiatry; 2010 Sep; 18(9):801-9. PubMed ID: 20220577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.